Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Shares Outstanding (Weighted Average): 2021-2024

Historic Shares Outstanding (Weighted Average) for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to $68.5 million.

  • Amylyx Pharmaceuticals' Shares Outstanding (Weighted Average) rose 30.97% to $89.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $89.2 million, marking a year-over-year increase of 30.97%. This contributed to the annual value of $68.5 million for FY2024, which is 1.53% up from last year.
  • According to the latest figures from FY2024, Amylyx Pharmaceuticals' Shares Outstanding (Weighted Average) is $68.5 million, which was up 1.53% from $67.5 million recorded in FY2023.
  • In the past 5 years, Amylyx Pharmaceuticals' Shares Outstanding (Weighted Average) ranged from a high of $68.5 million in FY2024 and a low of $57.9 million during FY2021.
  • In the last 3 years, Amylyx Pharmaceuticals' Shares Outstanding (Weighted Average) had a median value of $67.5 million in 2023 and averaged $67.4 million.
  • Data for Amylyx Pharmaceuticals' Shares Outstanding (Weighted Average) shows a peak YoY grew of 14.50% (in 2022) over the last 5 years.
  • Over the past 4 years, Amylyx Pharmaceuticals' Shares Outstanding (Weighted Average) (Yearly) stood at $57.9 million in 2021, then rose by 14.50% to $66.3 million in 2022, then grew by 1.90% to $67.5 million in 2023, then increased by 1.53% to $68.5 million in 2024.